Skip to content
    Leaps by Bayer logo

    Leaps by Bayer

    Leverkusen, GermanyFounded 2015
    leaps.bayer.comLinkedIn
    Biotech & Life SciencesFood & AgricultureHealthcare

    Leaps by Bayer is the corporate venture capital and impact investment arm of Bayer AG, investing in paradigm-shifting breakthroughs across life sciences, health, and agriculture. It backs early-to-late-stage companies pursuing fundamental scientific advances.

    35% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 5 prior). Average disclosed round size is $74.2M (across 59 rounds with reported amounts).

    Find people at Leaps by Bayer on Goldilocks AI

    Portfolio

    58

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    2

    Team

    SR

    Sören Roth

    Global HR Business Partner

    BK

    Brendan Kelly

    Senior Director of Health Venture Investments

    DB

    Denise Boehme

    Director Portfolio Strategy & Reporting

    KR

    Karyn Riegel

    Deputy Director of Brand & Community Engagement

    KP

    Kira Peikoff

    Deputy Director Communications

    SO

    Sara Olson

    Senior Director of Agriculture Venture Investments

    SN

    Steven Neier

    Senior Director, Healthcare Venture Investments

    AG

    André Guillaume

    VP / Head of Brand & Community Engagement

    DN

    Derek Norman

    Vice President, Venture Investments

    PA

    Paimun Amini

    VP of Agriculture Venture Investments

    NP

    Neele Piekarz

    Brand & Community Engagement Associate

    RD

    Rakhshita Dhar

    Healthcare venture investments

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    66 investments
    CompanyRoundAmountDate
    SSoufflé TherapeuticsSeries A—Aug 2026
    Celea Therapeutics logoCelea TherapeuticsSeed$180MJan 2026
    NuCicer logoNuCicerSeries A$11.5MJul 2025
    One Bio logoOne BioSeries A$27MDec 2024
    Nuvig Therapeutics logoNuvig TherapeuticsSeries B$161MDec 2024
    Pairwise logoPairwiseSeries C$40MSep 2024
    Transcarent logoTranscarentSeries D$126MMay 2024
    Summer Health logoSummer HealthSeries A$11.7MApr 2024
    9am Health logo9am HealthSeries A$9.5MFeb 2024
    Sudo Biosciences logoSudo BiosciencesSeries B$147MJan 2024
    Sudo logoSudoSeries B$147MJan 2024
    Transcarent logoTranscarentSeries D$126MJan 2024
    NewLeaf Symbiotics logoNewLeaf SymbioticsSeries D$45MDec 2023
    65LAB logo65LABUnknown—Oct 2023
    Chrysalabs logoChrysalabsSeries A$11MMay 2023
    Paratus Sciences logoParatus SciencesSeries D$100MFeb 2023
    EarthOptics logoEarthOpticsSeries B$27.6MJan 2023
    Sound Agriculture logoSound AgricultureSeries D$75MDec 2022
    9am Health logo9am HealthSeries A$16MApr 2022
    Dewpoint Therapeutics logoDewpoint TherapeuticsSeries C$150MFeb 2022
    Cellino logoCellinoSeries A$75MJan 2022
    AAda HealthSeries B$120MJan 2022
    Bloom Science logoBloom ScienceSeries A$12MDec 2021
    MedArrive logoMedArriveSeries A$25MNov 2021
    DDeka BiosciencesSeries A$20MNov 2021
    Page 1 of 3

    Top Co-Investors

    Alexandria Venture Investments9 shared
    S2G Ventures7 shared
    Polaris Partners6 shared
    ARCH Venture Partners5 shared
    Lux Capital5 shared
    7wire Ventures5 shared
    General Catalyst4 shared
    Fall Line Capital4 shared
    Mutschler Ventures4 shared
    Vitruvian Partners4 shared
    Human Ventures4 shared
    Sanofi Ventures4 shared
    OrbiMed3 shared
    RA Capital Management3 shared
    Illumina Ventures3 shared
    Cavallo Ventures3 shared
    Mirae Asset3 shared
    Mubadala Ventures3 shared
    Samsara BioCapital3 shared
    Casdin Capital3 shared

    Last updated: 7 September 2026